You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Mallinckrodt
Medtronic
AstraZeneca
Express Scripts

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLOZARIL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Clozaril

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00206778 Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania Completed Beth Israel Medical Center Phase 2 2003-07-01 We are comparing the efficacy of Lamotrigine to that of Standard of Care Sodium Valproate for the treatment of Mixed Mania. The study hypothesis is that Lamotrigine will be more efficative for treating mixed mania in patients with Bipolar Disorder.
NCT00312598 Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine Completed Bristol-Myers Squibb Phase 4 2005-08-01 Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring in those on the other atypical antipsychotics as well. We, the researchers at the University of North Carolina, propose an open-label observational, pilot study of the changes in weight, BMI, body composition, and lipids, glucose, insulin and other metabolic parameters occurring in subjects as they switch from treatment with olanzapine, risperidone or quetiapine to aripiprazole. This medication switch will be determined prior to their entering this study by their treating psychiatrist. We also will determine resting energy expenditure (REE) and respiratory quotient (RQ) as measured by metabolic cart to determine if either energy expenditure or the propensity to store energy as fat may be involved in any changes to weight that are detected. Food intake, hunger, and physical activity will also be assessed.
NCT00312598 Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine Completed University of North Carolina, Chapel Hill Phase 4 2005-08-01 Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring in those on the other atypical antipsychotics as well. We, the researchers at the University of North Carolina, propose an open-label observational, pilot study of the changes in weight, BMI, body composition, and lipids, glucose, insulin and other metabolic parameters occurring in subjects as they switch from treatment with olanzapine, risperidone or quetiapine to aripiprazole. This medication switch will be determined prior to their entering this study by their treating psychiatrist. We also will determine resting energy expenditure (REE) and respiratory quotient (RQ) as measured by metabolic cart to determine if either energy expenditure or the propensity to store energy as fat may be involved in any changes to weight that are detected. Food intake, hunger, and physical activity will also be assessed.
NCT00833976 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Completed GlaxoSmithKline Phase 4 2009-07-01 This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
NCT00833976 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Completed Massachusetts General Hospital Phase 4 2009-07-01 This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
NCT01654601 A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg Completed DongGuk University Phase 1 2012-06-01 To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.
NCT01654601 A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg Completed Konkuk University Hospital Phase 1 2012-06-01 To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clozaril

Condition Name

Condition Name for Clozaril
Intervention Trials
Schizophrenia 4
Schizoaffective Disorder 3
High Triglycerides 1
Bipolar Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clozaril
Intervention Trials
Schizophrenia 5
Disease 3
Psychotic Disorders 3
Bipolar Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clozaril

Trials by Country

Trials by Country for Clozaril
Location Trials
United States 2
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clozaril
Location Trials
Massachusetts 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clozaril

Clinical Trial Phase

Clinical Trial Phase for Clozaril
Clinical Trial Phase Trials
Phase 4 4
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clozaril
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clozaril

Sponsor Name

Sponsor Name for Clozaril
Sponsor Trials
Beth Israel Deaconess Medical Center 1
Bristol-Myers Squibb 1
Naju National Hospital 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clozaril
Sponsor Trials
Other 16
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Moodys
Dow
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.